Valuation: Axonics, Inc.

Market Cap 362.77Cr 314.05Cr 293.54Cr 268.28Cr 505.56Cr 35TCr 513.47Cr 3.44TCr 1.35TCr 17TCr 1.36TCr 1.33TCr 58TCr P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 331.04Cr 286.58Cr 267.87Cr 244.82Cr 461.34Cr 32TCr 468.55Cr 3.14TCr 1.23TCr 16TCr 1.24TCr 1.22TCr 53TCr EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 74 08/04/2019
Director/Board Member 69 01/02/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.10% - - 362.77Cr
+2.00%+1.35%-8.41%+22.19% 13TCr
+0.38%-7.64%-17.53%-1.65% 1.26TCr
+0.78%+6.17%+114.32%+145.69% 1.07TCr
+0.30%-0.35%-42.48%-67.21% 471.68Cr
-0.79%+3.51%-24.77%+37.61% 267.78Cr
-0.73%+14.36%-24.54%-75.80% 172.65Cr
+0.98%+1.30%-14.30%-12.41% 170.36Cr
+0.69%-2.02%-33.31%-31.58% 167.33Cr
Average +0.28%+0.64%-6.38%+2.11% 2.11TCr
Weighted average by Cap. +1.55%+2.60%-2.99%+24.11%

Financials

2022 2023
Net sales 27Cr 24Cr 22Cr 20Cr 38Cr 2.61TCr 39Cr 259.71Cr 101.91Cr 1.31TCr 102.77Cr 100.53Cr 4.35TCr 37Cr 32Cr 30Cr 27Cr 51Cr 3.49TCr 52Cr 347.65Cr 136.41Cr 1.75TCr 137.57Cr 134.57Cr 5.82TCr
Net income -5.97Cr -5.17Cr -4.83Cr -4.41Cr -8.32Cr -569.36Cr -8.45Cr -57Cr -22Cr -284.84Cr -22Cr -22Cr -948.67Cr -60.88L -52.7L -49.26L -45.02L -84.84L -58Cr -86.17L -5.78Cr -2.27Cr -29Cr -2.29Cr -2.24Cr -97Cr
Net Debt -35Cr -30Cr -28Cr -26Cr -49Cr -3.32TCr -49Cr -330.3Cr -129.61Cr -1.66TCr -130.71Cr -127.85Cr -5.53TCr -32Cr -27Cr -26Cr -23Cr -44Cr -3.03TCr -45Cr -301.12Cr -118.16Cr -1.51TCr -119.16Cr -116.56Cr -5.04TCr
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB